NF-kappaB and not the MAPK signaling pathway regulates GADD45beta expression during acute inflammation.
The GADD45 (growth arrest and DNA damage-inducible) family of genes is involved in the regulation of cell cycle progression and apoptosis. To study signaling pathways affecting GADD45beta expression and to examine systematically in vivo the GADD45beta expression in tissues following various toxic stresses, we created a transgenic mouse by fusing the GADD45beta promoter to firefly luciferase (Gadd45beta-luc). In vivo GADD45beta expression was assessed by measuring the luciferase activity in the Gadd45beta-luc transgenic mouse using a non-invasive imaging system (IVIS Imaging System, Xenogen Corporation). We found that a number of agents that induce oxidative stress, such as sodium arsenite, CCl4, lipopolysaccharide (LPS), or tumor necrosis factor-alpha, are able to induce luciferase expression throughout the entire animal. In liver, spleen, lung, intestine, kidney, and heart, we observed an induction of luciferase activity after LPS treatment, which correlates with an increase of GADD45beta mRNA in these tissues. Processes that induce DNA damage activate the NF-kappaB signaling pathway. Several inhibitors of the NF-kappaB signaling pathway, including dexamethasone, thalidomide, and a proteasome inhibitor, bortezomib, showed inhibitory effects on LPS-induced GADD45beta expression as indicated by a decrease of the luciferase activity. Northern blot analysis confirmed a broad inhibitory effect of bortezomib on LPS-induced GADD45beta mRNA expression in spleen, lung, and intestine. In liver of bortezomib-treated mice, we observed a reverse correlation between the luciferase activity and the GADD45beta mRNA level. We speculate that such a discrepancy could be due to severe liver toxicity caused by bortezomib and LPS co-treatment. MAPK inhibitors had transient and inconsistent effects on LPS-induced luciferase expression. Our data are consistent with the notion that NF-kappaB, but not the MAPK signaling pathways, is involved in the in vivo regulation of GADD45beta expression. Thus, NF-kappaB signaling involves induction of GADD45beta expression, which supports the proposed role of GADD45beta in protecting cells against DNA damaged under various stress conditions.
Zhang
Ning
N
Xenogen Corporation, Alameda, California 94501, USA. ning.zhang@xenogen.com
Ahsan
Muhammad H
MH
Zhu
Leanne
L
Sambucetti
Lidia C
LC
Purchio
Anthony F
AF
West
David B
DB
D000818:Animals; D000943:Antigens, Differentiation / Q000737:chemistry* / Q000378:metabolism; D017209:Apoptosis; D018053:Arsenites / Q000494:pharmacology; D015152:Blotting, Northern; D015153:Blotting, Western; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D004249:DNA Damage; D003907:Dexamethasone / Q000494:pharmacology; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005260:Female; D015723:Gene Library; D005822:Genetic Vectors; D020672:I-kappa B Proteins / Q000378:metabolism; D007249:Inflammation; D008070:Lipopolysaccharides / Q000378:metabolism / Q000494:pharmacology; D008156:Luciferases / Q000378:metabolism; D020935:MAP Kinase Signaling System; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D018384:Oxidative Stress; D011401:Promoter Regions, Genetic; D061988:Proteasome Inhibitors; D011485:Protein Binding; D011719:Pyrazines / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D015398:Signal Transduction; D017670:Sodium Compounds / Q000494:pharmacology; D013792:Thalidomide / Q000494:pharmacology; D013997:Time Factors; D014018:Tissue Distribution; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D000097642:GADD45 Proteins
D000943:Antigens, Differentiation; D018053:Arsenites; D001897:Boronic Acids; D000069286:Bortezomib; D003907:Dexamethasone; D048049:Extracellular Signal-Regulated MAP Kinases; D020672:I-kappa B Proteins; D008070:Lipopolysaccharides; D008156:Luciferases; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B; D061988:Proteasome Inhibitors; D011719:Pyrazines; D012333:RNA, Messenger; D017670:Sodium Compounds; D013792:Thalidomide; D014409:Tumor Necrosis Factor-alpha; C086470:GADD45B protein, human; D000097642:GADD45 Proteins; C000606204:NFKBIA protein, human; C000606205:Nfkbia protein, mouse; C017947:sodium arsenite